rs367956522
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000053.4(ATP7B):c.2731-2A>G variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000434 in 1,613,950 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000053.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP7B | NM_000053.4 | c.2731-2A>G | splice_acceptor_variant | ENST00000242839.10 | NP_000044.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATP7B | ENST00000242839.10 | c.2731-2A>G | splice_acceptor_variant | 1 | NM_000053.4 | ENSP00000242839 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152186Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000242 AC: 6AN: 248258Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 134902
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461646Hom.: 0 Cov.: 36 AF XY: 0.0000358 AC XY: 26AN XY: 727110
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152304Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74480
ClinVar
Submissions by phenotype
Wilson disease Pathogenic:13
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 08, 2022 | The ATP7B c.2731-2A>G variant (rs367956522) is reported in the literature in multiple individuals affected with Wilson disease (Bost 2012, Coffey 2013, Mukherjee 2014, Shah 1997). This variant is reported by multiple laboratories in ClinVar (Variation ID: 188725), and is found in the general population with an overall allele frequency of 0.002% (7/279650 alleles) in the Genome Aggregation Database. This variant abolishes the canonical splice acceptor site of intron 11, and has been shown to alter splicing, causing an in-frame insertion of 39 nucleotides (Shah 1997), which is likely to disrupt gene function. Based on available information, this variant is considered to be pathogenic. REFERENCES Bost M et al. Molecular analysis of Wilson patients: direct sequencing and MLPA analysis in the ATP7B gene and Atox1 and COMMD1 gene analysis. J Trace Elem Med Biol. 2012 Jun;26(2-3):97-101. PMID: 22677543. Coffey AJ et al. A genetic study of Wilson's disease in the United Kingdom. Brain. 2013 May;136(Pt 5):1476-87. PMID: 23518715. Mukherjee S et al. Genetic defects in Indian Wilson disease patients and genotype-phenotype correlation. Parkinsonism Relat Disord. 2014 Jan;20(1):75-81. PMID: 24094725. Shah AB et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet. 1997 Aug;61(2):317-28. PMID: 9311736. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | This sequence change affects an acceptor splice site in intron 11 of the ATP7B gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individuals with Wilson disease (PMID: 9311736, 23518715; Invitae). ClinVar contains an entry for this variant (Variation ID: 188725). Studies have shown that disruption of this splice site results in skipping of exon 12 and insertion of additional nucleotides, but is expected to preserve the integrity of the reading-frame (PMID: 9311736). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 04, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Mar 20, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 01, 2023 | This variant causes an A to G nucleotide substitution at the -2 position of intron 11 of the ATP7B gene. This variant has been reported in over ten individuals affected with Wilson disease (PMID: 9311736, 22677543, 23518715, 24094725; ClinVar: SCV000926218.1). In eight affected individuals, this variant has been determined to be homozygous or compound heterozygous with another pathogenic variant in the same gene, indicating that this variant contributes to Wilson disease in an autosomal recessive manner. RT-PCR analysis using cells derived from a homozygous individual revealed that this variant results in two aberrant transcripts, one with entire exon 12 (c.2731-2865; p.911-955) skipped and the other with in-frame insertion of 13 amino acids at the beginning of exon 12 due to the use of a cryptic acceptor site, 39-bp upstream from the native acceptor site (PMID: 9311736). This variant is expected to disrupt functionally important Actuator (phosphatase) domain (a.a. 786 - 917) and transmembrane M3 domain (a.a. 918 - 946). This variant has been identified in 7/279650 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 19, 2016 | Variant summary: The ATP7B c.2731-2A>G variant located at a conserved intronic position, known to affect splicing with 5/5 splice prediction tools predicting a significant effect on splicing, which has been functionally supported (Shah_1997). This mutation produces 13 additional amino acids (VVISHGLGVLFSW) in the region between the transduction motif and the fifth Tm region. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/119818 (1/59909), which does not exceed the estimated maximal expected allele frequency for a pathogenic ATP7B variant of 1/185. Multiple publications cite the variant in affected individuals including a homozygous individual, along with a reputable clinical laboratory citing the variant as "likely pathogenic." Therefore, the variant of interest has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Sep 08, 2022 | This ATP7B canonical splice site variant (rs367956522) has been reported in the literature in association with Wilson disease. It is rare (<0.1%) in a large population dataset (gnomAD: 7/279650 total alleles; MAF 0.002503%; 0 homozygotes), and has an entry in ClinVar (Variation ID 188725). This variant destroys a canonical splice acceptor site, is predicted to cause abnormal gene splicing, and has supporting functional evidence. We consider this variant to be pathogenic. - |
Pathogenic, criteria provided, single submitter | research | Laboratory for Population and Evolutionary Genetics, University of Puerto Rico at Mayaguez | Feb 22, 2019 | dbSNP:rs367956522 in ATP7B has been reported segregating with Wilson's Disease in the UK with compound heterozygous in 3 cases (Coffey et al. 2013, PMID 23518715), and in the USA in both homozygous and compound heterozygous forms (Shah et al. 1997, PMID 9311736). In our unpublished study, all 4 individuals diagnosed with Wilson's Disease in southwestern Puerto Rico were homozygous for the minor allele. By contrast, none of the 214 healthy individuals tested were homozygous, In summary, dbSNP:rs367956522 is classified as pathogenic/likely pathogenic but meets our criteria to be classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 28, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 13, 2021 | The c.2731-2A>G variant in ATP7B has been previously reported in individuals with Wilson disease, including at least 3 compound heterozygotes (Bost 2012 PMID: 22677543, Coffey 2013 PMID: 23518715, Mukherjee 2014 PMID: 24094725, Shah 1997 PMID: 9311736). In addition, RT-PCR analysis performed on lymphoblast culture from patients harboring the variant revealed an in-frame 39-bp insertion derived from a cryptic splice site (Shah 1997 PMID: 9311736). This variant has also been identified in 3/35320 Latino chromosomes by gnomAD (http://gnomad.broadinstitute.org). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Wilson disease. ACMG/AMP criteria applied: PVS1_Strong, PM3_Strong, PM2_Supporting, PP4. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 20, 2017 | The c.2731-2A>G pathogenic variant in the ATP7B gene has been reported previously in the homozygous state in association with Wilson disease (Shah et al., 1997). This splice site variant destroys the canonical splice acceptor site in intron 11. Sequencing of mutant APT7B RNA shows exon 12 skipping as well as an insertion of 13 amino acids, due to the use of a cryptic splice acceptor site (Shah et al., 1997). The c.2731-2A>G variant was not observed with any significant frequency in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret c.2731-2A>G as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 16, 2022 | PM2, PM3, PS3, PVS1_strong - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 17, 2017 | The c.2731-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 12 in the ATP7B gene. This mutation was detected in a homozygous individual with Wilson disease who presented with neurological symptoms and liver disease. Functional studies showed that this mutation leads to abnormal splicing (Shah AB et al. Am. J. Hum. Genet., 1997 Aug;61:317-28). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
ATP7B-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 05, 2024 | The ATP7B c.2731-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in individuals with Wilson disease (Table 2, Shah et al. 1997. PubMed ID: 9311736; Table 1, Bost et al. 2012. PubMed ID: 22677543; Table 1, Mukherjee et al. 2013. PubMed ID: 24094725; pedigree 1, Coffey et al. 2013. PubMed ID: 23518715). RT-PCR from patient lymphoblast cells revealed this variant abolishes the exon 12 splice site and results in an in-frame inclusion of thirteen additional amino acids (Figure 1, Shah et al. 1997. PubMed ID: 9311736). This variant is reported in 0.0085% of alleles in individuals of Latino descent in gnomAD and has an interpretation of pathogenic and likely pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/188725/). Variants that disrupt the consensus splice acceptor site in ATP7B are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at